Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 12/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 4/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | BMX | P51813 | 2/20 | 0.34 |
| ▸ | ITK | Q08881 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31008584 | 1.00 | HCRTR1 (0.39) | HCRTR1HCRTR2CYP3A4CCNCCDK8 | |
| SCHEMBL29333580 | 0.91 | CCNC (0.36) | HCRTR1HCRTR2CYP3A4CCNCCDK8 | |
| SCHEMBL29333401 | 0.89 | CCNC (0.35) | HCRTR1HCRTR2CYP3A4CCNCCDK8 | |
| SCHEMBL29333520 | 0.89 | CCNC (0.39) | HCRTR1HCRTR2CYP3A4CCNCCDK8 | |
| SCHEMBL31008613 | 0.89 | CCNC (0.35) | HCRTR1HCRTR2CYP3A4CCNCCDK8 | |
| SCHEMBL29333510 | 0.89 | CCNC (0.35) | HCRTR1HCRTR2CYP3A4CCNCCDK8 | |
| SCHEMBL30855121 | 0.88 | BTK (0.36) | HCRTR1HCRTR2CYP3A4CCNCCDK8 | |
| SCHEMBL29333515 | 0.88 | BTK (0.36) | HCRTR1HCRTR2CYP3A4CCNCCDK8 | |
| SCHEMBL29333504 | 0.88 | HCRTR1 (0.41) | HCRTR1HCRTR2CYP3A4CCNCCDK8 | |
| SCHEMBL29333522 | 0.86 | FGFR4 (0.36) | HCRTR1HCRTR2CCNCCDK8BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | HCRTR1 3277/4885HCRTR2 3315/4885CYP3A4 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.